Who are Ketamina-Propofol Combination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CT-guided corticosteroid+ bupivicaine, Ropivacaine, Ketorolac and Adrenaline, Fentanyl/Atropine/Succinylcholine, Dexamethasone+ Bupivacaine, Hydrocortisone acetate and lidocaine hydrochloride, Lidocaine-chlorprocaine combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketamina-propofol-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ketamina-Propofol Combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketamina-Propofol Combination (Ketamina-Propofol Combination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anesthetic combination. Area: Anesthesiology.

marketed Anesthetic combination NMDA receptor (ketamine); GABA-A receptor (propofol) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Ketamina-Propofol Combination (Ketamina-Propofol Combination) — Universidad de Cartagena. A combination of ketamine (NMDA receptor antagonist) and propofol (GABA-A agonist) that produces rapid anesthesia and sedation through dual CNS depression pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ketamina-Propofol Combination TARGET	Ketamina-Propofol Combination	Universidad de Cartagena	marketed	Anesthetic combination	NMDA receptor (ketamine); GABA-A receptor (propofol)
CT-guided corticosteroid+ bupivicaine	CT-guided corticosteroid+ bupivicaine	Montefiore Medical Center	marketed	Corticosteroid + local anesthetic combination injection
Ropivacaine, Ketorolac and Adrenaline	Ropivacaine, Ketorolac and Adrenaline	University of Aarhus	marketed	Local anesthetic combination with NSAID and vasopressor	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline)
Fentanyl/Atropine/Succinylcholine	Fentanyl/Atropine/Succinylcholine	King Saud University	marketed	Anesthetic combination (opioid + anticholinergic + neuromuscular blocker)	Mu-opioid receptor (fentanyl); muscarinic acetylcholine receptors (atropine); nicotinic acetylcholine receptors at neuromuscular junction (succinylcholine)
Dexamethasone+ Bupivacaine	Dexamethasone+ Bupivacaine	Ain Shams University	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)
Hydrocortisone acetate and lidocaine hydrochloride	Hydrocortisone acetate and lidocaine hydrochloride	Citius Pharmaceuticals, Inc.	marketed	Topical corticosteroid and local anesthetic combination	Glucocorticoid receptor (hydrocortisone); voltage-gated sodium channels (lidocaine)
Lidocaine-chlorprocaine combination	Lidocaine-chlorprocaine combination	Hadassah Medical Organization	marketed	Local anesthetic combination	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anesthetic combination class)

Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
Kasr El Aini Hospital · 1 drug in this class
Universidad de Cartagena · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketamina-Propofol Combination — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamina-propofol-combination. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing